KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vertex Pharmaceuticals (VRTX) Interest Expenses (2018 - 2025)

Historic Interest Expenses for Vertex Pharmaceuticals (VRTX) over the last 10 years, with Q4 2025 value amounting to $3.3 million.

  • Vertex Pharmaceuticals' Interest Expenses rose 1785.71% to $3.3 million in Q4 2025 from the same period last year, while for Dec 2025 it was $13.3 million, marking a year-over-year decrease of 5653.59%. This contributed to the annual value of $13.3 million for FY2025, which is 5653.59% down from last year.
  • As of Q4 2025, Vertex Pharmaceuticals' Interest Expenses stood at $3.3 million, which was up 1785.71% from $3.3 million recorded in Q3 2025.
  • Over the past 5 years, Vertex Pharmaceuticals' Interest Expenses peaked at $11.2 million during Q2 2023, and registered a low of $2.8 million during Q4 2024.
  • In the last 3 years, Vertex Pharmaceuticals' Interest Expenses had a median value of $7.5 million in 2024 and averaged $7.0 million.
  • As far as peak fluctuations go, Vertex Pharmaceuticals' Interest Expenses crashed by 7358.49% in 2024, and later soared by 1785.71% in 2025.
  • Over the past 3 years, Vertex Pharmaceuticals' Interest Expenses (Quarter) stood at $10.6 million in 2023, then plummeted by 73.58% to $2.8 million in 2024, then rose by 17.86% to $3.3 million in 2025.
  • Its Interest Expenses stands at $3.3 million for Q4 2025, versus $3.3 million for Q3 2025 and $3.7 million for Q2 2025.